RCT | Gefitinib plus chemotherapy vs. Gefitinib alone in untreated EGFR-mutant NSCLC with brain metastases

Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study – JAMA Network Open

Commentary on Twitter

RCT: In patients with untreated EGFR-mutated non-small cell lung cancer with brain metastases, gefitinib + chemo improved survival and PFS vs gefitinib, with manageable adverse events, and may be a viable first-line treatment. #NSCLC https://t.co/Oe6zHYVsPV pic.twitter.com/oUvs12pYS7

— JAMA Network Open (@JAMANetworkOpen) February 9, 2023